Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal Cancer

18 Oct 2016

Abstract excerpt

AIM: Increased DNA methylation within the promoter regions of tumor suppressor genes has been associated with gene silencing in various cancers. CDX2, a caudal-related homeobox transcription factor, represents a key tumor suppressor in colorectal cancer. However, the pathological role of its promoter methylation has not yet been well defined in colorectal cancer. METHODS: We measured CDX2 promoter methylation by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Digestive system and related health
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27754705
DOI: 10.1089/gtmb.2016.0136

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal CancerPMID 27754705Read ↗

Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.Semantic proximity Read ↗

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal CancerSemantic proximity Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.Semantic proximity Read ↗

CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwaySemantic proximity Read ↗

Altered expression of CDX2 in colorectal cancersSemantic proximity Read ↗

CDX2 polymorphisms, RNA expression, and risk of colorectal cancer.Semantic proximity Read ↗

Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer.Semantic proximity Read ↗

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.Semantic proximity Read ↗

Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.Semantic proximity Read ↗

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerSemantic proximity Read ↗

CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.